Fractional Flow Reserve Versus Angiography for Guiding Selective Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 600
- 主要终点
- Major adverse cardiac events
研究概览
简要总结
To assess the outcomes of patients with ST-segment elevation myocardial infarction (STEMI) assigned to fractional flow reserve (FFR) and angiography-guided selective percutaneous coronary intervention (PCI).
详细描述
The investigators retrospectively collect STEMI patients received selective PCI from Jan 2012 to Dec 2015. Clinical follow-up is performed from the date of FFR assessment to Dec 2016 or death, which is up to 5 years. The primary endpoint is major adverse cardiac events, composite of cardiac death, reinfarction and unplanned hospitalization due to cardiovascular reasons. The primary endpoints are cardiac death, reinfarction and unplanned hospitalization due to cardiovascular reasons. All deaths are considered cardiovascular unless an unequivocal noncardiac cause could be established. Reinfarction is defined as myocardial infarction after the PCI procedure. Unplanned hospitalization will be present only if the patient is hospitalized unexpectedly because of persisting or increasing complaints of angina, ventricular arrhythmias and heart failure. All patients were received FFR-guided PCI or angiography-guided PCI before enrollment, and the investigators do not assign specific interventions to the subjects during the study. So this study might be considered to be observational.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age>18 years
- •documented acute ST-segment elevation myocardial infarction
- •onset of symptom >6 days before percutaneous coronary intervention
- •eligible for PCI
排除标准
- •cardiogenic shock or hemodynamic instability
- •highly tortuous or calcified arteries
- •infarct related artery with a diameter < 2.5mm
- •a life expectancy< 2 years
- •intolerance to anti-platelet drugs
- •left main disease (≥ 50% stenosis)
- •contraindication to adenosine
- •hypertrophic cardiomyopathy
结局指标
主要结局
Major adverse cardiac events
时间窗: up to 5 years
composite of cardiac death, reinfarction and unplanned hospitalization due to cardiovascular reasons
次要结局
- cardiac death(up to 5 years)
- unplanned hospitalization due to cardiovascular reasons(up to 5 years)
- reinfarction(up to 5 years)
研究者
Jin Geng
MD
Nanjing Medical University
